PolyPid (PYPD) has released an update.
PolyPid Ltd., a biopharma company focused on improving surgical outcomes, has enrolled approximately 320 patients in its SHIELD II Phase 3 trial for preventing abdominal colorectal surgical site infections with D-PLEX100. The firm anticipates conducting an interim analysis in Q4 2024 and expects top-line results in Q1 2025. Additionally, PolyPid has secured financing to extend its cash runway into Q2 2025, ensuring support for the SHIELD II trial’s advancement.
For further insights into PYPD stock, check out TipRanks’ Stock Analysis page.
